- Trials with a EudraCT protocol (402)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
402 result(s) found for: Neoplasms AND Ovarian Cancer.
Displaying page 9 of 21.
| EudraCT Number: 2016-000065-23 | Sponsor Protocol Number: C/30/2011 | Start Date*: 2018-06-05 | |||||||||||||||||||||
| Sponsor Name:Imperial College London | |||||||||||||||||||||||
| Full Title: An international multi-centre randomised phase II study to assess the efficacy of TAK228 in combination with intravenous weekly paclitaxel compared with weekly paclitaxel alone in women with advanc... | |||||||||||||||||||||||
| Medical condition: Ovarian, fallopian tube or primary peritoneal cancer of clear cell, endometrioid or high grade serous subtype or carcinosarcoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2019-002474-30 | Sponsor Protocol Number: 2019-002474-30 | Start Date*: 2019-12-20 | |||||||||||
| Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
| Full Title: PERSONALIZED MOLECULAR DRIVEN SURGERY ACCORDING TO BRCA MUTATIONAL STATUS IN ADVANCED EPITHELIAL OVARIAN CANCER PATIENTS WITH HIGH TUMOR LOAD | |||||||||||||
| Medical condition: ADVANCED OVARIAN CARCINOMA | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-003926-18 | Sponsor Protocol Number: MITO28/MANGOOV4 | Start Date*: 2018-11-19 | ||||||||||||||||
| Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE | ||||||||||||||||||
| Full Title: A phase II clinical trial of Pembrolizumab in combination with Carboplatin-Paclitaxel in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer: MITO28/MANG... | ||||||||||||||||||
| Medical condition: advanced (stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-000146-33 | Sponsor Protocol Number: MITO33 | Start Date*: 2020-10-09 | |||||||||||||||||||||
| Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||||||||||||
| Full Title: Randomized phase III trial on NIraparib-TSR-042 (dostarlimab) vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platin... | |||||||||||||||||||||||
| Medical condition: Recurrent ovarian, fallopian tube or primary peritoneal cancer. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: IT (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) GR (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2022-003662-21 | Sponsor Protocol Number: ALKS4230-003 | Start Date*: 2023-04-13 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Alkermes, Inc. | ||||||||||||||||||||||||||||||||||||||
| Full Title: Clinical and Immunologic Activity of Nemvaleukin Alfa With a Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumo... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Patients with advanced solid malignancies | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-000825-18 | Sponsor Protocol Number: CSET2020/3047 | Start Date*: 2020-05-12 | |||||||||||
| Sponsor Name:Gustave Roussy | |||||||||||||
| Full Title: An open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNATM, a DNA repair inhibitor, administered intravenously in addition to Niraparib in patients with relapsed p... | |||||||||||||
| Medical condition: Relapsed platinum sensitive ovarian cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-000177-31 | Sponsor Protocol Number: CAN-004AB | Start Date*: 2012-10-18 | |||||||||||
| Sponsor Name:Prima BioMed Ltd | |||||||||||||
| Full Title: CANVAS: A Randomized Trial of Cvac (Autologous Dendritic Cells Pulsed with Recombinant Human Fusion Protein [Mucin 1-Glutathione S Transferase] Coupled to Oxidized Polymannose) as Maintenance Treat... | |||||||||||||
| Medical condition: Maintenance Treatment in [A] Patients with Epithelial Ovarian Cancer (EOC) in Complete Remission Following First-Line Chemotherapy and [B] Patients with EOC in Second Remission | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: LT (Prematurely Ended) BG (Prematurely Ended) DE (Prematurely Ended) BE (Completed) LV (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-000348-11 | Sponsor Protocol Number: EC-FV-06 | Start Date*: 2011-11-14 | |||||||||||
| Sponsor Name:Endocyte, Inc. | |||||||||||||
| Full Title: A RANDOMIZED DOUBLE-BLIND PHASE 3 TRIAL COMPARING VINTAFOLIDE (EC145) AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD/DOXIL®/CAELYX®) IN COMBINATION VERSUS PLD IN PARTICIPANTS WITH PLATINUM-RESISTANT OVAR... | |||||||||||||
| Medical condition: Platinum Resistant Ovarian Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: CZ (Prematurely Ended) ES (Completed) BE (Prematurely Ended) PL (Prematurely Ended) HU (Prematurely Ended) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-003078-21 | Sponsor Protocol Number: XTX202-01/02-001 | Start Date*: 2023-03-28 | |||||||||||||||||||||||||||||||
| Sponsor Name:Xilio Development, Inc | |||||||||||||||||||||||||||||||||
| Full Title: A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors | |||||||||||||||||||||||||||||||||
| Medical condition: Advanced solid tumors | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: HU (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2022-002877-27 | Sponsor Protocol Number: CTRIAL-IE-21-29/NRG-GY019 | Start Date*: 2023-07-06 | ||||||||||||||||
| Sponsor Name:Cancer Trials Ireland | ||||||||||||||||||
| Full Title: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or P... | ||||||||||||||||||
| Medical condition: Primary low-grade serous carcinoma of the ovary or peritoneum. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: IE (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2017-000161-75 | Sponsor Protocol Number: UCL/14/0795 | Start Date*: 2017-12-18 | |||||||||||
| Sponsor Name:University College London | |||||||||||||
| Full Title: An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer... | |||||||||||||
| Medical condition: High grade serous or endometrioid ovarian, fallopian and peritoneal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-004618-93 | Sponsor Protocol Number: R120502 | Start Date*: 2017-12-12 | ||||||||||||||||
| Sponsor Name:University of Manchester | ||||||||||||||||||
| Full Title: Evaluation of the safety of CEdiranib in the prevention of Bowel perforation in platinum-resistant Ovarian Cancer | ||||||||||||||||||
| Medical condition: Platinum-Resistant Ovarian Cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2015-005137-42 | Sponsor Protocol Number: Debio1143-EOC-203 | Start Date*: 2016-04-29 | |||||||||||
| Sponsor Name:Debiopharm International SA | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Neoadjuvant Carboplatin and Paclitaxel, With or Without Debio 1143 in Patients With Newly Diagnosed Advanced Epithelial Ovarian Cancer. | |||||||||||||
| Medical condition: Newly Diagnosed Advanced Epithelial Ovarian Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) BE (Completed) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-002480-94 | Sponsor Protocol Number: 69HCL17_0342 | Start Date*: 2021-07-21 | |||||||||||
| Sponsor Name:Hospices Civils de Lyon | |||||||||||||
| Full Title: Assessment of cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in first or secondary platinum-resistant recurrent ovarian epithelial cancer. HIPOVA-01 | |||||||||||||
| Medical condition: Patients with First or second recurrence of platin-resistant epithelial ovarian cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-002841-39 | Sponsor Protocol Number: GINECO-OV-222 | Start Date*: 2013-10-07 | |||||||||||
| Sponsor Name:ARCAGY GINECO | |||||||||||||
| Full Title: A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by bevacizumab monotherapy maintenance versus weekly paclitaxel followed by observation in patients with rela... | |||||||||||||
| Medical condition: Patients with an histologically confirmed diagnosis of ovarian sex-cord stromal tumor in relapse after a platinum-based chemotherapy. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-005471-24 | Sponsor Protocol Number: GINECO-OV236b | Start Date*: 2016-04-19 | ||||||||||||||||
| Sponsor Name:ARCAGY-GINECO | ||||||||||||||||||
| Full Title: A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chem... | ||||||||||||||||||
| Medical condition: Patients with late relapse of epithelial ovarien cancer, fallopian tube or peritoneal cancer treated with chemotherapy , bevacizumab and a anti PD-L1 | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: FR (Completed) ES (Ongoing) AT (Completed) DE (Completed) BE (Completed) CZ (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2012-001962-13 | Sponsor Protocol Number: CBYL719X2105J | Start Date*: 2012-11-29 | |||||||||||||||||||||
| Sponsor Name:Novartis Farmaceutica S.A | |||||||||||||||||||||||
| Full Title: A phase Ib/II open-label, multi-center study of the combination of BYL719 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors | |||||||||||||||||||||||
| Medical condition: Solid tumors Hormone receptor positive breast cancer Ovarian cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Completed) BE (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2017-002904-29 | Sponsor Protocol Number: INCB01158-203 | Start Date*: 2017-12-20 | |||||||||||||||||||||||||||||||
| Sponsor Name:Incyte Corporation | |||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors. | |||||||||||||||||||||||||||||||||
| Medical condition: Phase 1: Advanced or metastatic solid tumors Phase 2: Advanced/metastatic microsatellite stable colorectal cancer (MSS-CRC), biliary tract cancer (BTC), gastroesophageal cancer (GC), and endometri... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-002036-24 | Sponsor Protocol Number: Uni-koeln-1612 | Start Date*: 2014-06-24 | |||||||||||
| Sponsor Name:University of Cologne | |||||||||||||
| Full Title: A non-randomised, non-comparative monocenter investigator initiated trial to assess the efficacy and safety of Carmustine in patients with BRCA1/2-associated advanced breast and ovarian cancer | |||||||||||||
| Medical condition: Patients with BRCA1- or BRCA2-associated advanced breast- and ovarian cancer which are refractory to standard therapy and for which no suitable, effective/curative therapy exists. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-002667-53 | Sponsor Protocol Number: 213409 | Start Date*: 2021-08-23 | |||||||||||||||||||||
| Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||||||||||||
| Full Title: An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and are Judged by the Investigator to Benefit... | |||||||||||||||||||||||
| Medical condition: advanced ovarian, breast, or prostate cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: AT (Trial now transitioned) FR (Trial now transitioned) DK (Completed) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
